SpaceX-linked investors commit $41 million to psychedelic drug development post-FDA rejection

Eli Lilly's $2.8 billion acquisition of AtaiBeckley in July 2025, plus up to $1 billion in milestones for BPL-003 in treatment-resistant depression, marks the first major pharmaceutical entry into the sector. WSJ reporting confirms additional commitments from Steve Cohen and Pritzker family members. PSIL ETF has outperformed the S&P 500 by 32 percent year-to-date while select names gained 79 to 171 percent. The shift draws capital previously allocated to technology into regulatory-dependent drug pipelines. Retail investors tracking these moves interpret billionaire participation as de-risking, prompting inflows into volatile small-cap names despite incomplete clinical data. This reallocates attention from software multiples toward FDA timelines and Phase 3 endpoints. Historical patterns show similar retail enthusiasm clusters around regulatory milestones rather than revenue, amplifying price swings once initial validation is priced in. Next catalysts include Resilient's revised MDMA filing and any follow-on Lilly disclosures on pipeline integration. Sustained outperformance above 50 percent relative to the S&P through 2026 would require at least one additional large-cap acquisition or positive pivotal trial readout.